Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) rose Wednesday, on announcing a notice of grant of new European patent covering sapacitabine pharmaceutical formulations.
The company, based out of Berkeley Heights, New Jersey, announced the receipt of a notice from the European Patent Office of the intention to grant a patent including claims to novel pharmaceutical formulations of sapacitabine.
The European patent will provide exclusivity until December 2026 excluding any extensions. Equivalent patents have been granted in the United States and other countries.
According to CEO Spiro Rombotis, "This European notice of grant enhances the intellectual property estate related to sapacitabine. The relevant patent family is an important layer of our strategy of building on sapacitabine's exclusivity. It supplements existing composition of matter, dosing regimen and combination treatment patent protection in major global markets extending into 2030."
Sapacitabine, an orally-available nucleoside analogue, is currently being studied in an ongoing, Phase 1 study evaluating a sequential regimen of sapacitabine and seliciclib, a first generation CDK inhibitor. Parts 1 and 2 of the study evaluated an enriched population of approximately 76 patients with advanced cancers and were reported at ASCO 2016.
The ongoing extension of part 1 enrolled 20 patients with BRCA positive advanced breast cancers and is in the follow-up stage. Part 3 of the study has been opened for enrolment with the objective of testing a revised dosing schedule in additional patients, including BRCA positive patients with advanced ovarian and pancreatic cancers.
The shares moved into noon hour Wednesday ahead six cents, or 3.6%, from Tuesday’s close, to $1.61.
Related Stories
